BioCryst Pharmaceuticals Inc. Common Stock (BCRX)

FairStock Score: 95/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, BioCryst traded at $8.07 with a $2.1 billion market cap. The filed figures show revenue rising from $331.4 million in FY2023 to $450.7 million in FY2024 and $874.8 million in FY2025. In the fiscal Q2 2026 quarter ended 2026-06-30, revenue was $218.3 million and net income $78.4 million, or $0.30 diluted EPS. But the fiscal Q1 2026 quarter ended 2026-03-31 had a net loss of $721.8 million and diluted EPS of -$2.98, so the earnings record is volatile. TTM free cash flow is $373.4 million, and FairStock calculates an 18.1% FCF yield at that close. FairStock also shows a negative P/E of -5.76 and EPS of -$1.40, which makes trailing earnings useless as a valuation anchor. The Piotroski F-Score is 8/9, and ROCE is 52.86%, both FairStock calculations, suggesting some operating and accounting strength. The Altman Z-Score of -2.61, also FairStock, warns of financial distress risk. The Lynch category is TURNAROUND — Returned to profit after a loss within the last three years. BioCryst sells ORLADEYO for hereditary angioedema and peramivir for influenza, so it has specialized products, but I cannot call that a wide moat from the data alone. If the free cash flow is durable, the market is pricing it cheaply; if the large loss repeats or cash flow fades, the apparent value is fragile. I would demand consistent net income and a stronger balance sheet before trusting the turnaround.

In plain English: BioCryst makes medicines for rare diseases, including hereditary angioedema and influenza. The business has grown sales and recently became profitable, but one quarter showed a very large loss, so results are uneven. At $8.07, the price looks inexpensive compared with the cash the business generated over the past year, though the risk is whether that cash and profit can continue.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer